BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
74.59
-0.93 (-1.23%)
At close: Apr 10, 2026, 4:00 PM EDT
74.05
-0.54 (-0.72%)
After-hours: Apr 10, 2026, 5:57 PM EDT
BridgeBio Pharma Revenue
In the year 2025, BridgeBio Pharma had annual revenue of $502.08M with 126.26% growth. BridgeBio Pharma had revenue of $154.18M in the quarter ending December 31, 2025, with 2,521.18% growth.
Revenue (ttm)
$502.08M
Revenue Growth
+126.26%
P/S Ratio
28.80
Revenue / Employee
$598,422
Employees
839
Market Cap
14.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 502.08M | 280.17M | 126.26% |
| Dec 31, 2024 | 221.90M | 212.60M | 2,285.27% |
| Dec 31, 2023 | 9.30M | -68.35M | -88.02% |
| Dec 31, 2022 | 77.65M | 7.93M | 11.38% |
| Dec 31, 2021 | 69.72M | 61.47M | 745.14% |
| Dec 31, 2020 | 8.25M | -32.31M | -79.66% |
| Dec 31, 2019 | 40.56M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 5.14B |
| Jazz Pharmaceuticals | 4.27B |
| Genmab | 3.72B |
| BioMarin Pharmaceutical | 3.22B |
| Exelixis | 2.32B |
| Madrigal Pharmaceuticals | 958.40M |
| Ionis Pharmaceuticals | 943.71M |
| Ascendis Pharma | 845.52M |
BBIO News
- 11 days ago - Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54 - GlobeNewsWire
- 11 days ago - BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9 - GlobeNewsWire
- 18 days ago - BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions - GlobeNewsWire
- 21 days ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress - Benzinga
- 4 weeks ago - BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 - GlobeNewsWire
- 4 weeks ago - BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz - Benzinga
- 5 weeks ago - BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference - GlobeNewsWire